Thiopurine S-Methyltransferase Polymorphisms in Korean Dermatologic Patients.
- Author:
Minseok LEE
1
;
Jimyung SEO
;
Dongsik BANG
;
Do Young KIM
Author Information
- Publication Type:Original Article
- Keywords: Azathioprine; Behcet syndrome; Dermatology; Thiopurine S methyltranferase deficiency
- MeSH: 6-Mercaptopurine; Alleles; Asian Continental Ancestry Group; Azathioprine; Behcet Syndrome; Dermatology; Drug-Related Side Effects and Adverse Reactions; Genotype; Humans; Korea; Leukopenia; Mass Screening; Medical Records; Metabolism; Retrospective Studies; Thioguanine
- From:Annals of Dermatology 2017;29(5):529-535
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Thiopurine S-methyltransferase (TPMT) is an important enzyme in the metabolism of thiopurines including azathioprine (AZA), 6-mercaptopurine, and 6-thioguanine. TPMT genotyping is widely used for screening of AZA-related toxicity during routine clinical practice in Korea. However, the data of TPMT genotypes and its AZA-related toxicity have not been studied in the field of dermatology. OBJECTIVE: The aim of this study was to evaluate the genetic basis of TPMT polymorphism in Korean dermatologic patients and subsequently to investigate the relationship between mutant TPMT and adverse responses to AZA treatment. METHODS: This study was retrospective, single-center study. One hundred forty-nine Korean dermatologic patients who underwent TPMT screening test were included. Each patient's medical records, the result of TPMT screening test, dose and treatment period of AZA, and side effects, were reviewed. Laboratory tests were assessed at each visit in order to monitor adverse drug reactions. Leukopenia grading was used in accordance with the common terminology criteria for adverse events (CTCAE) ver. 4.03. RESULTS: Behçet's disease was the leading disorder among the patients. The frequency of TPMT mutation was 4.0% (6/149) among the participants in this study. Four of the six patients with genetic alterations were treated with a low-dose AZA regimen, but no AZA-related adverse events were observed. CONCLUSION: Our results suggest that 1) TPMT polymorphisms in Korean dermatologic patients are similar to those previously reported in Asian patients with the most common mutant allele being TPMT*3C and 2) AZA can be used in the patients with these polymorphisms under a careful dosing regimen.
